浦江国际(02060.HK)拟1.04亿元收购上海普实26%股权 后者正备战科创板
格隆汇9月1日丨浦江国际(02060.HK)宣布,于2019年8月29日,公司非全资附属上海浦江缆索作为买方与公司关连人士奥盛集团作为卖方订立股权转让协议,据此,买方拟向卖方购买其所持上海普实26%股权,购买价为人民币1.04亿元。上海普实主要从事开发医疗设备技术以及生产及销售医疗设备,专攻心脏相关疾病,其产品以PushMed®商标营销及销售。
上海普实的产品组合由六个PushMed®设备组成,包括(i)左心耳封堵器系统;(ii)房间隔缺损封堵器;(iii)室间隔缺损(“VSD”)封堵器;(iv)动脉导管未闭封堵器;(v)封堵器介入输送装置及(vi)室间隔缺损封堵治疗使用的抓捕器。该等设备已获得专利并取得相关医疗器械注册证书。上海普实已取得于中国制造及销售其PushMed®植入设备及技术的相关许可证。尤其是,上海普实的左心耳封堵器系统获认可为高度创新技术,因此,根据相关中国法律及法规获许于其产品注册申请时享受国家药品监督管理局的优先待遇。该设备亦已纳入上海市政府医疗保险计划项下的获批医疗器械清单。目前,上海普实的产品管线包括房间隔穿刺系统及二尖瓣修复系统。
上海普实于2012年创办,于数年间在研发及生产心脏相关疾病的植入设备及系统方面成功建立其影响力。自其成立起,其PushMed®设备及技术已获中国医院于多项心脏手术中使用。于2019年9月1日,上海普实已注册并维护18项专利及已自欧盟、印度及中国的相关政府机构取得销售其设备的批文。此外,根据市场数据,由于人口老龄化催生对该等心脏手术设备的需求,预期相关业务需求将持续增加。作为上海普实业务发展及策略的一部份,上海普实正筹备申请于上海证券交易所科创板的上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.